Results 151 to 160 of about 20,847 (278)

Collagen‐membrane‐covered matrix‐associated chondrocyte implantation improves safety over periosteum‐covered MACI for large knee cartilage defects: A real‐world data analysis in the registry study

open access: yesKnee Surgery, Sports Traumatology, Arthroscopy, EarlyView.
Abstract Purpose This registry study aimed to evaluate the safety and effectiveness of collagen membrane‐covered matrix‐associated autologous chondrocyte implantation (cMACI) versus periosteum‐covered MACI (pMACI) for large knee cartilage defects (Outerbridge III–IV, ≥4 cm²) in the femorotibial and/or patellofemoral joints with a minimum 2‐year follow ...
Yuji Uchio   +4 more
wiley   +1 more source

Eliciting Mental Time Travel Through Digital Product Displays and Its Positive Influence on Purchase‐Oriented Outcomes

open access: yesPsychology &Marketing, EarlyView.
ABSTRACT Drawing on cognitive science research, this study explores mental time travel and its elicitation through digital product displays. Specifically, we examine how digital product displays elicit mental time travel to the past and future and how this cognitive process positively influences three purchase‐oriented outcomes: inspiration to purchase,
Jennifer Brannon Barhorst   +3 more
wiley   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri   +20 more
wiley   +1 more source

Hepatosplenic cat-scratch fever with seropositivity for Bartonella quintana? [PDF]

open access: yes, 2008
INCANDELA, Salvatore   +4 more
core   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy